Noven shares slide as therapy flunks Phase III

Shares of Noven Pharmaceuticals were trimmed 16 percent this morning after researchers announced that a late-stage therapy for bipolar disorder had flunked its Phase III trial. The once daily lithium treatment, Lithium QD, was not significantly effective in treating acute mania. That had to be particularly bad news at Noven, which acquired the therapy when it bought JDS Pharmaceuticals earlier this year.

"Both the Noven and JDS teams are very surprised and disappointed that the study did not achieve its primary endpoint," said Noven CEO Robert Strauss. "We are currently analyzing the data to determine why statistical efficacy was not achieved."

- see this release on the data
- here's the MarketWatch report

Related Articles:
Noven garners $25M payday on sales milestone. Report
Noven expands pipeline with $125M JDS buyout. Report
FDA rejects Noven's copycat version of Duragesic pain patch. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.